> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Cybrexa Therapeutics to Begin Cancer Trial of CBX-12
- URL: https://www.fdaweb.com/cybrexa-therapeutics-to-begin-cancer-trial-of-cbx-12/
- Published: 2021-03-22T12:00:00.000Z
- Updated: 2026-09-14T16:51:44.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5148934

FDA has given Cybrexa Therapeutics the green light to begin a clinical trial for solid tumor therapy CBX-12 (alphalex-exatecan). “Preclinical studies of CBX-12 show a strong efficacy and safety profile, and we expect that the Phase 1 clinical trial will help us learn more about the potential applications of this therapeutic candidate,” the company says. CBX-12 is described by Cybrexa as a novel treatment for solid tumors that includes a highly potent topoisomerase I inhibitor payload that is in the same class as the payloads used by antibody-drug conjugates Enhertu (Daiichi Sankyo) and Trodelvy (Immunomedics). CBX-12 is able to target cancer cells independent of antigen expression unlike Enhertu and Trodelvy, it says, adding that this could greatly expand the addressable patient populations. The planned Phase 1 trial of CBX-12 is expected to begin next month.